Pharmacology Research Today is a free monthly online journal that collates and summarizes the latest research about Pharmacology, including details on pharmacogenomics, drug development, new medications.

Volume 2 (2006), Issue 7 (July)

1. History of toxicology and allied sciences: a bibliographic review and guide to suggested readings.
   Int J Toxicol, 25(4): 261-8. [Abstract] [Full-text]
2. Pharmacognostic standardization of Turnera aphrodisiaca Ward.
   J Med Food, 9(2): 254-60. [Abstract] [Full-text]
3. Model-based drug development: the road to quantitative pharmacology.
   J Pharmacokinet Pharmacodyn, 33(3): 369-93. [Abstract] [Full-text]
4. The comparative toxicogenomics database: a cross-species resource for building chemical-gene interaction networks.
   Toxicol Sci, 92(2): 587-95. [Abstract] [Full-text]
5. A system-based approach to interpret dose- and time-dependent microarray data: quantitative integration of gene ontology analysis for risk assessment.
   Toxicol Sci, 92(2): 560-77. [Abstract] [Full-text]
6. Pharmacokinetic-pharmacodynamic modelling: history and perspectives.
   J Pharmacokinet Pharmacodyn, 33(3): 227-79. [Abstract] [Full-text]
7. ExpoFacts--an overview of European exposure factors data.
   Risk Anal, 26(3): 831-43. [Abstract] [Full-text]
8. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study.
   J Acquir Immune Defic Syndr, 42(4): 441-9. [Abstract] [Full-text]
9. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology.
   Chem Res Toxicol, 19(7): 889-93. [Abstract] [Full-text]
10. How omics technologies can contribute to the '3R' principles by introducing new strategies in animal testing.
    Trends Biotechnol, 24(8): 343-6. [Abstract] [Full-text]
11. Pediatric gastrointestinal motility--future directions and challenges.
    Dig Dis, 24(3): 308-12. [Abstract] [Full-text]
12. A novel RBF neural network training methodology to predict toxicity to Vibrio fischeri.
    Mol Divers, 10(2): 213-21. [Abstract] [Full-text]
13. Megavariate analysis of environmental QSAR data. Part II--investigating very complex problem formulations using hierarchical, non-linear and batch-wise extensions of PCA and PLS.
    Mol Divers, 10(2): 187-205. [Abstract] [Full-text]
14. Megavariate analysis of environmental QSAR data. Part I--a basic framework founded on principal component analysis (PCA), partial least squares (PLS), and statistical molecular design (SMD).
    Mol Divers, 10(2): 169-86. [Abstract] [Full-text]
15. True prediction of lowest observed adverse effect levels.
    Mol Divers, 10(2): 159-68. [Abstract] [Full-text]
16. Using high-throughput screening data to discriminate compounds with single-target effects from those with side effects.
    J Chem Inf Model, 46(4): 1549-62. [Abstract] [Full-text]
17. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.
    Blood, 108(3): 1065-72. [Abstract] [Full-text]
18. Precision-cut organ slices to investigate target organ injury.
    Expert Opin Drug Metab Toxicol, 1(4): 687-99. [Abstract] [Full-text]
19. Psychopharmacology: clinical implications of brain neurochemistry.
    Pediatr Clin North Am, 53(4): 767-75. [Abstract] [Full-text]
20. Pediatric ethics in the age of molecular medicine.
    Pediatr Clin North Am, 53(4): 639-48. [Abstract] [Full-text]
21. Pharmacogenomics and the future of drug therapy.
    Pediatr Clin North Am, 53(4): 591-619. [Abstract] [Full-text]
22. Genetic variants and the risk of Crohn's disease: what does it mean for future disease management?
    Expert Opin Pharmacother, 7(12): 1591-602. [Abstract] [Full-text]
23. Pharmacogenetics of antiarrhythmic therapy.
    Expert Opin Pharmacother, 7(12): 1583-90. [Abstract] [Full-text]
24. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
    Drug Metab Rev, 38(3): 393-409. [Abstract] [Full-text]

© 2005-2008 Pharmacology Research Today. All Rights Reserved.